BACKGROUND: Rotavirus is the major cause of gastroenteritis in children throughout the world. Every year, a large number of children aged < 5 years die from rotavirus-related diarrhoeal diseases. Though these infections are vaccine-preventable, the vast majority of children in low-income countries suffer from the infection. The situation leads to severe economic loss and constitutes a major public health problem. METHODS: We searched electronic databases including PubMed and Google scholar using the following words: "features of rotavirus," "epidemiology of rotavirus," "rotavirus serotypes," "rotavirus in Bangladesh," "disease burden of rotavirus," "rotavirus vaccine," "low efficacy of rotavirus vaccine," "inactivated rotavirus vaccine". Publications until July 2017 have been considered for this work. RESULTS AND CONCLUSION: Currently, two live attenuated vaccines are available throughout the world. Many countries have included rotavirus vaccines in national immunization program to reduce the disease burden. However, due to low efficacy of the available vaccines, satisfactory outcome has not yet been achieved in developing countries such as Bangladesh. Poor economic, public health, treatment, and sanitation status of the low-income countries necessitate the need for the most effective rotavirus vaccines. Therefore, the present scenario demands the development of a highly effective rotavirus vaccine. In this regard, inactivated rotavirus vaccine concept holds much promise for reducing the current disease burden. Recent advancements in developing an inactivated rotavirus vaccine indicate a significant progress towards disease prophylaxis and control.
BACKGROUND: Rotavirus is the major cause of gastroenteritis in children throughout the world. Every year, a large number of children aged < 5 years die from rotavirus-related diarrhoeal diseases. Though these infections are vaccine-preventable, the vast majority of children in low-income countries suffer from the infection. The situation leads to severe economic loss and constitutes a major public health problem. METHODS: We searched electronic databases including PubMed and Google scholar using the following words: "features of rotavirus," "epidemiology of rotavirus," "rotavirus serotypes," "rotavirus in Bangladesh," "disease burden of rotavirus," "rotavirus vaccine," "low efficacy of rotavirus vaccine," "inactivated rotavirus vaccine". Publications until July 2017 have been considered for this work. RESULTS AND CONCLUSION: Currently, two live attenuated vaccines are available throughout the world. Many countries have included rotavirus vaccines in national immunization program to reduce the disease burden. However, due to low efficacy of the available vaccines, satisfactory outcome has not yet been achieved in developing countries such as Bangladesh. Poor economic, public health, treatment, and sanitation status of the low-income countries necessitate the need for the most effective rotavirus vaccines. Therefore, the present scenario demands the development of a highly effective rotavirus vaccine. In this regard, inactivated rotavirus vaccine concept holds much promise for reducing the current disease burden. Recent advancements in developing an inactivated rotavirus vaccine indicate a significant progress towards disease prophylaxis and control.
Authors: K Zaman; Duc Anh Dang; John C Victor; Sunheang Shin; Md Yunus; Michael J Dallas; Goutam Podder; Dinh Thiem Vu; Thi Phuong Mai Le; Stephen P Luby; Huu Tho Le; Michele L Coia; Kristen Lewis; Stephen B Rivers; David A Sack; Florian Schödel; A Duncan Steele; Kathleen M Neuzil; Max Ciarlet Journal: Lancet Date: 2010-08-06 Impact factor: 79.321
Authors: Jagdish K Zade; Prasad S Kulkarni; Sajjad A Desai; Rajendra N Sabale; Sameer P Naik; Rajeev M Dhere Journal: Vaccine Date: 2014-08-11 Impact factor: 3.641
Authors: Manish Patel; Andi L Shane; Umesh D Parashar; Baoming Jiang; Jon R Gentsch; Roger I Glass Journal: J Infect Dis Date: 2009-11-01 Impact factor: 5.226
Authors: Caitlin Naylor; Miao Lu; Rashidul Haque; Dinesh Mondal; Erica Buonomo; Uma Nayak; Josyf C Mychaleckyj; Beth Kirkpatrick; Ross Colgate; Marya Carmolli; Dorothy Dickson; Fiona van der Klis; William Weldon; M Steven Oberste; Jennie Z Ma; William A Petri Journal: EBioMedicine Date: 2015-09-25 Impact factor: 8.143
Authors: Arif Mohammad Tanmoy; Asm Nawshad Uddin Ahmed; Rajesh Arumugam; Belal Hossain; Mahfuza Marzan; Shampa Saha; Shams El Arifeen; Abdullah H Baqui; Robert E Black; Gagandeep Kang; Samir Kumar Saha Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240